Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc has exhibited robust growth in Chromium reaction volumes, indicating a strong market demand for its integrated solutions amid challenging conditions in the pharmaceutical sector. The company's consumables are projected to experience significant growth, with anticipated increases ranging from 5 to 19 times by 2027, outpacing revenue growth from instruments. This trend suggests a solid foundation for the company's financial performance, reflecting the ongoing alignment of its offerings with the complexities of biological systems.

Bears say

10x Genomics has experienced a significant contraction in its market performance, with double-digit pricing pressures and flat to declining volumes expected to persist until 2027. The company reported weaker-than-anticipated fourth-quarter earnings, with a miss in earnings per share and a full-year revenue outlook that fell below expectations. Furthermore, despite some growth in its market segments since the stock's peak in 2021, the expansion has not met analyst projections, contributing to a decline of over 90% in the stock price from its previous highs.

10X Genomics (TXG) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 13 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.